Xcout IntelSign inSubscribe

PACIFIC EDGE LIMITED competitors & alternatives

PEBPharmaceuticals, Biotechnology & Life SciencesDunedin, New Zealand

The 12 closest competitors and alternatives to PACIFIC EDGE LIMITED among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what PACIFIC EDGE LIMITED actually does, not by market-cap band.

$187.8MMarket cap
114Employees
12Competitors listed

Subscribe to see PACIFIC EDGE LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About PACIFIC EDGE LIMITED

Pacific Edge Ltd is a biotechnology research company headquartered in Dunedin, New Zealand, specializing in genomic diagnostics and the commercialization of the Cxbladder family of tests.

PACIFIC EDGE LIMITED at a glance

PACIFIC EDGE LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in Dunedin, New Zealand. It is publicly listed (PEB) with a market capitalisation of $187.8M. Xcout tracks 4 named people at PACIFIC EDGE LIMITED, including Jon E Bortz (Chairman & Chief Executive Officer).

PACIFIC EDGE LIMITED leadership

  • Jon E BortzChairman & Chief Executive Officer
  • Thomas Charles FisherCo-President & Chief Investment Officer
  • Raymond D. MartzCo-President, Chief Financial Officer, Treasurer & Secretary
  • Andrew H. DittamoVice President & Controller

Top 12 PACIFIC EDGE LIMITED competitors

Ranked by semantic similarity — how close each company is to PACIFIC EDGE LIMITED by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

PROTEOMICS INTERNATIONAL LABORATORIES LTDPIQ · Pharmaceuticals, Biotechnology & Life SciencesNedlands, Australia
63% matchPublic

Similar pharmaceuticals, biotechnology & life sciences company

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.

Market cap$18.8M
Employees161
PROTEOMICS INTERNATIONAL LABORATORIES LTD competitors & alternatives →
GENETIC TECHNOLOGIES LIMITEDGTG · Pharmaceuticals, Biotechnology & Life SciencesFitzroy, Australia
63% matchPublic

Similar pharmaceuticals, biotechnology & life sciences company

Genetic Technologies Limited (GTG.AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health. The company operates through two distinct divisions: EasyDNA and GeneType/Corporate. Among its offerings is BREVAGenplus, a clinically validated test specifically designed for assessing the risk of non-hereditary breast cancer. This product is actively promoted to healthcare providers such as obstetricians/gynecologists, breast surgeons, and specialists in breast health and imaging centers. GTG.AX also provides an array of cancer risk assessment tests, notably GeneType for Colorectal Cancer and GeneType for Breast Cancer, and is currently developing new risk assessments for conditions including ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. In addition to its diagnostic services, the company offers broader genetic testing solutions spanning medical, animal, forensic, and plant applications. Genetic Technologies Limited has established research and collaboration agreements with several prominent institutions, including the University of Melbourne, Translational Genomics Research Institute, and Memorial Sloan Kettering New York Cambridge University.

Market cap$4M
Employees55
GENETIC TECHNOLOGIES LIMITED competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of PACIFIC EDGE LIMITED and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for PACIFIC EDGE LIMITEDand every competitor above — in one live dashboard.

Subscribe to Xcout Intel →